Lyfegen offers a fully automated rebate management platform that delivers secure, real‑time tracking, compliance, and operational efficiency for complex drug pricing agreements. The company maintains a large digital repository of innovative drug pricing models and public agreements and provides a drug pricing simulator to model financial impacts. Its solutions are used by 50+ healthcare organisations across eight geographical markets to manage 4,000+ rebate agreements, track over $1 billion in pharmaceutical revenue, and administer over $0.5 billion in rebates annually. Lyfegen serves health insurers, governments, hospital payers, and pharmaceutical companies and aims to simplify pricing complexity and accelerate access to modern treatments. The company was founded in 2018 and is headquartered in Basel, Switzerland, with market presence in Europe, North America, and the Middle East. Recently it closed an additional CHF 5 million Series A to support global expansion and further product innovation. Lyfegen provides a patent-pending software analytics platform that digitizes the end-to-end process of data collection, anonymization and contract negotiations to operationalize value- and outcome-based agreements. The platform uses real-world data and machine learning to identify and scale value-based payment models for health insurers, hospitals, regulators and pharma. Lyfegen's customers include leading pharma companies (Novartis, Roche, MSD, Bristol Myers Squibb and Johnson & Johnson) and government payers and insurers in Europe, the U.S. and the Middle East. The company positions its solution as a response to rising specialty drug costs and the growth of cell and gene therapies, which increase demand for value-based contracting. Lyfegen plans to further expand its presence in the U.S., partnering with both private and public healthcare insurance companies. Financially, the company completed an oversubscribed $8 million Series A to support its expansion and product growth. Lyfegen HealthTech, based in Basel, Switzerland, has developed a patent-pending software platform that analyzes complex healthcare datasets to support value-based healthcare contracting. The platform is designed to help patients access innovative therapies and to enable life sciences companies, payers, and providers to develop and roll out digital value-based care. Some of the world’s 10-largest pharmaceutical and medical technology companies are already using the platform in strategic markets in Europe and South America. The company raised seed capital in April 2019 and has additional funding and founders' contributions supporting its operations. The new financing will be used to strengthen Lyfegen’s market position in the U.S., additional European markets, and Latin America, with a focus on oncology, rare diseases, and medical devices. Co‑founders include Girisha Fernando, Michel Mohler, Nico Mros, and Leon Rebolledo. Lyfegen HealthTech AG, based in Basel, Switzerland, has developed a platform that collects, analyzes and reconciles disparate healthcare data to automate value-based healthcare contracting. The solution enables life sciences companies, national and private healthcare payers, and healthcare providers to operationalize healthcare strategies and run operations from a single platform. The system supports personalized healthcare by enabling patient-level pricing, which the company says can accelerate and facilitate access to innovative treatments. Founded in October 2018 by Girisha Fernando, Michel Mohler, Nico Mros, Leon Rebolledo and James Gannon, Lyfegen plans to use the funds to further build its payments platform. The company will also conduct additional pilots with partners in the US, Africa and the EU, including the UK. Lyfegen closed a CHF750K seed financing round led by Swiss private investors.

Total raised

$17M

Funding rounds

4

Latest round

Series A

Latest activity

Dec 2024